2020 US Democrat presidential candidates speak to seniors on Rx prices

2 August 2019
ussenate-big

How will US Democratic presidential candidates lower drug prices for seniors if they become President? This is a question many will be asking ahead of the US elections.

Seventeen candidates recently spoke to advocacy group AARP - the American Association of Retired Persons - and the Des Moines Register about high prescription costs and their broader health care plan. Here are some of their views.

Former Vice President Joe Biden: “I would set up an independent commission at the Department of Health and Human Services that would bring in experts from around the country that would, in fact, take a look at the research and the cost of going in to develop that drug, and set the initial price of that drug. After that, if they get a patent on that drug … they cannot raise it beyond the cost of inflation at that time.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical